Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Mequitazine, a phenothiazine derivative, is a 2nd generation antihistamine, histamine H1 antagonist, with antimuscarinic and mild sedative properties. It is used in allergic diseases such as urticaria, pruritus, rhinitis and conjunctivitis. Oral administration twice daily.
At the time of the last update, we found no published data on its excretion in breast milk.
The paucity of published pharmacokinetic data prevents prediction of possible excretion into breast milk. Other known safer antihistamines are preferable, especially during the neonatal period and in case of prematurity.
Follow-up for sedation and feeding ability of the infant. Bed-sharing is not recommended for mothers who are taking this medication. (UNICEF 2018, 2017, 2014, 2013 y 2006, Landa 2012, ABM 2008)